Immunome, Inc. Profile Avatar - Palmy Investing

Immunome, Inc.

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoti…

Biotechnology
US, Exton [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Immunome, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Immunome, Inc. can't present revenue by segment

End of IMNM's Analysis
CIK: 1472012 CUSIP: 45257U108 ISIN: US45257U1088 LEI: - UEI: -
Secondary Listings
IMNM has no secondary listings inside our databases.